Dr. George R. Blumenschein, Jr., M.D., is a Professor of Medicine in the Department of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He received his B.A. from Vanderbilt University and his M.D. from the University of Texas Medical School in Houston. He completed his residency in internal medicine at The University of Texas Health Science Center in Houston and his fellowship training in medical oncology at The University of Texas MD Anderson Cancer Center. He is a member of the American Society of Clinical Oncology (ASCO), Society for Immunotherapy of Cancer (SITC), National Cancer Institute’s SWOG organization, NRG Oncology Lung Committee, International Association for the Study of Lung Cancer (IASLC) and American Association for Cancer Research (AACR).

Dr. Blumenschein’s area of focus is in new drug development, adoptive T cell therapy and multimodality therapy for the treatment of lung and head and neck cancers. He serves as the Thoracic Medical Oncology Deputy Section Chief, Director of the Department’s Cellular Therapies Program, and leads the Department’s Phase I efforts. Specifically, he is interested in the application of compounds with novel mechanisms of action to treat these tumor types. In addition to authoring and co-authoring numerous papers and book chapters regarding the management of these cancers, he has also served as the principle investigator on a number of research protocols and has clinical expertise in early phase first-in-human (FIH) studies applying adoptive T cell therapies for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Most recently, he led an early phase FIH study of a novel anti-MAGE x CD3 T cell engaging bispecific against a sub-population of advanced solid tumors.